Edition:
United Kingdom

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.82EUR
21 Aug 2018
Change (% chg)

€0.02 (+0.17%)
Prev Close
€11.80
Open
€11.84
Day's High
€11.90
Day's Low
€11.80
Volume
5,280
Avg. Vol
45,223
52-wk High
€15.00
52-wk Low
€9.51

Latest Key Developments (Source: Significant Developments)

Biocartis Group Launches Innovative Idylla Msi Assay
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Biocartis Group NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES INNOVATIVE IDYLLA(TM) MSI ASSAY.IDYLLA MSI ASSAY PROVIDES INFORMATION ON MSI STATUS (I.E. MSI-HIGH OR MICROSATELLITE STABLE) OF A TUMOR WITHIN APPROXIMATELY 150 MIN FROM JUST ONE SLICE OF FFPE TUMOR TISSUE, WITHOUT REQUIRING A REFERENCE SAMPLE.  Full Article

Biocartis' Idylla EGFR Mutation Test Able To Produce Result In 80 Percent Of Failed Next Generation Sequencing Lung Cancer Tests, According To Study
Monday, 28 May 2018 

May 28 (Reuters) - Biocartis Group NV ::STUDY DEMONSTRATES ABILITY OF IDYLLA(TM) EGFR MUTATION TEST TO PRODUCE A RESULT IN 80% OF FAILED NEXT GENERATION SEQUENCING LUNG CANCER TESTS.  Full Article

Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS & IMMUNEXPRESS SIGN PARTNERSHIP FOR A SEPSIS HOST IMMUNE RESPONSE TEST ON THE IDYLLA™ PLATFORM.AGREEMENT TO DEVELOP, COMMERCIALIZE OF IMMUNEXPRESS’ SEPTICYPTE TEST FOR USE ON CO'S SAMPLETO-RESULT IDYLLA PLATFORM‍​.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - :BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED ON THE 80 MILLION EUROS DEAL SIZE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS PRICE GUIDANCE OF 12.50 EUROS PER SHARE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS CLOSE AT 1830 UK TIME.  Full Article

Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biocartis Group Nv's Bookrunner: :SAYS OFFERING OF UP TO ABOUT 8.9 MILLION SHARES ‍​.SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​.  Full Article

Biocartis Launches Equity Placement
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.‍EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 60 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING​.‍POSSIBILITY TO INCREASE SIZE OF OFFERING TO UP TO 8,933,950 NEW SHARES IN TOTAL​.‍BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY​.‍TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD​.‍J.P. MORGAN, DEGROOF PETERCAM, KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS IN OFFERING​.‍ENVISAGES USING NET PROCEEDS TO FUND EXPANSION OF IDYLLA TEST MENU AND APPLICATIONS​.‍TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING​.  Full Article

Biocartis Group sees ‍2017 guidance reiterated
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - BIOCARTIS GROUP NV ::SEES ‍2017 GUIDANCE REITERATED​.‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​.  Full Article

Biocartis and A*Star's ETPL initiate development of breast cancer assay
Monday, 10 Jul 2017 

July 10 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND A*STAR'S ETPL INITIATE DEVELOPMENT OF BREAST CANCER ASSAY TO GUIDE THERAPY SELECTION.  Full Article